Mark Throsby

Title: **Mark Throsby: A Pioneering Innovator in Therapeutic Antibodies**

Introduction

Mark Throsby is a prominent inventor based in Utrecht, Netherlands, with an impressive portfolio of 44 patents. His groundbreaking work primarily focuses on the development of bispecific antibodies for therapeutic applications, particularly in targeting cells that exhibit specific genomic features. Throsby’s research has significant implications for advancing cancer treatments.

Latest Patents

Among Throsby’s latest inventions are two notable patents: first, the development of ERBB-2 and ERBB-3 binding bispecific antibodies intended for the treatment of cells that possess an NRG1 fusion gene. This invention delves into the realm of therapeutic human antibodies, specifically targeting ErbB-2/ErbB-3 positive cells. It aims to treat cells that harbor an NRG1 fusion gene, which includes portions of the NRG1 gene fused with sequences from other chromosomal locations.

The second patent describes an antibody designed to bind both ErbB-2 and ErbB-3. This innovative antibody features a first antigen-binding site that attaches to Erb B-2 and a second that connects to Erb B-3, effectively diminishing ligand-induced receptor activity in Erb B-2 and Erb B-3 positive cells. Additionally, the patent outlines methods for treatment and the use of these antibodies in imaging and addressing tumors that are positive for either Erb B-2, Erb B-3, or both.

Career Highlights

Mark Throsby has built an esteemed career, contributing significantly to biomedical research. He has worked with notable companies, including Merus N.V. and Crucell Holland B.V., which have provided platforms for his innovative research in therapeutic antibodies. His contributions to the field are recognized through a growing number of patents and peer-reviewed publications.

Collaborations

Throughout his career, Throsby has partnered with esteemed colleagues, including Cornelis Adriaan De Kruif and Ton Logtenberg. These collaborations have played a crucial role in enhancing his research and expanding the impact of his innovations within the biopharmaceutical industry.

Conclusion

Mark Throsby stands as a testament to the transformative power of innovation in medicine. With a robust portfolio of patents and significant collaborations, his work continues to foster advancements in therapeutic antibodies, aiming to pioneer new treatments for serious medical conditions. His contributions not only highlight his expertise but also the collaborative spirit that drives innovation in the field of biotechnology.